Health News from Medical News Today: Clavis Pharma Receives Government Grant To Develop HENT1 Biomarker Assay For Targeted Therapy Of AML Patients

Health News from Medical News Today Latest Health News and Medical News posted throughout the day, every day. Clavis Pharma Receives Government Grant To Develop HENT1 Biomarker Assay For Targeted Therapy Of AML Patients 30 May 2011, 7:00 pm Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, is pleased to announce that it has been awarded a grant from The Research Council of Norway of up to NOK 14 mill (USD 2.5 mill) for the development of a flow cytometry method for the detection and quantification of human Equilibrative Nucleoside Transporter (hENT1) in patients suffering from Acute Myeloid Leukaemia (AML)... You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed.